QLS-111 Ophthalmic Solution (0.015%): Clinical Trials

1 active not recruiting, 1 completed. 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	2	Active not recruiting 1, Completed 1

Follow QLS-111 Ophthalmic Solution (0.015%): new trials by email Literature Review of QLS-111 Ophthalmic Solution (0.015%) trials Research Report on QLS-111 Ophthalmic Solution (0.015%)

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%) - Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG)	Phase 2	Active not recruiting	Qlaris Bio, Inc.	14	2026-02-20	2026-09-14
Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG) QLS-111 ophthalmic solution (0.015%), Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) - Normal Tension Glaucoma (NTG), Low-Tension Glaucoma, Bilateral	Phase 2	Completed	Qlaris Bio, Inc.	37	2025-08-13	2026-04-03

Conditions studied

Glaucoma (2)  ·  Low Tension Glaucoma (2)  ·  Diabetic Retinopathy (1)  ·  Glaucoma, Open-Angle (1)

Sponsors

Qlaris Bio, Inc. (2)

Countries

South Korea (1)  ·  United States (1)

Top investigators

Barbara M Wirostko, MD (1)  ·  Lisa Brandano (1)